PROCEPT BioRobotics Is Maintained at Buy by TD Cowen
PROCEPT BioRobotics Analyst Ratings
TD Cowen Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Raises Target Price to $99
Buy Rating Affirmed for PROCEPT BioRobotics on Hydros Platform Launch and Positive Long-Term Growth Outlook
Truist Financial Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Maintains Target Price $95
Truist Financial Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Announces Target Price $95
Analysts Offer Insights on Healthcare Companies: Inari Medical (NARI) and PROCEPT BioRobotics (PRCT)
Truist Financial Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating
BofA Securities Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Maintains Target Price $94
A Quick Look at Today's Ratings for PROCEPT BioRobotics(PRCT.US), With a Forecast Between $69 to $94
PROCEPT BioRobotics (PRCT) Gets a Buy From Truist Financial
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT) and Fate Therapeutics (FATE)
BTIG Keeps Their Hold Rating on PROCEPT BioRobotics (PRCT)
Buy Rating Affirmed for PROCEPT BioRobotics Following FDA Clearance and Launch of Hydros
Buy Rating Justified: PROCEPT BioRobotics's Technological Innovation and Market Growth Potential
Truist Financial Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating
TD Cowen Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Maintains Target Price $75
PROCEPT BioRobotics Analyst Ratings
Truist Securities Reiterates Buy on PROCEPT BioRobotics, Lowers Price Target to $74
A Quick Look at Today's Ratings for PROCEPT BioRobotics(PRCT.US), With a Forecast Between $69 to $80